{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:17:38Z","timestamp":1793089058304,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Prolactin (PRL)-secreting tumours are associated with infertility and can be reverted by dopamine agonist (DA) therapy. The suspension of DA is recommended once pregnancy is established, as all DAs cross the placenta. The aim of the study was to evaluate the rate of maternal-foetal complications in women treated with cabergoline (CAB) or bromocriptine (BRM) for prolactinoma during gestation and the effect of pregnancy on prolactinoma progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective observational study involving 43 women affected by prolactinoma who became pregnant during therapy with CAB or BRM for a total of 58 pregnancies. For each patient, medical records were analysed by integrating the data with outpatient or telephone interview.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the time of conception, 18 women were in the BRM group, while 40 were in CAB group. No differences were found in obstetric or neonatal outcomes between the two groups. There was a significant difference (p\u2009=\u20090.046) in child complications reported in maternal interview found exclusively in the CAB group. No further confounding factors were detected. Disease remission rate after the first pregnancy was 42.9% and the main predictor was a lower PRL nadir before pregnancy (p\u2009=\u20090.023). No difference was detected between the two groups in terms of tumor remission. Breastfeeding did not modify the outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Foetal exposure to DAs during the first weeks of embryogenesis is not associated with a greater risk of complications. The transient and mild developmental disorders recorded resolved spontaneously and the prevalence was substantially overlapping with that observed in the general population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-024-01384-1","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T19:01:32Z","timestamp":1710788492000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center"],"prefix":"10.1007","volume":"27","author":[{"given":"Nunzia","family":"Prencipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-2640","authenticated-orcid":false,"given":"Daniela","family":"Cuboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bioletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Varaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Simone","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sibilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","volume":"49","author":"AF Daly","year":"2020","unstructured":"Daly AF, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49:347\u2013355. https:\/\/doi.org\/10.1016\/j.ecl.2020.04.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1384_CR2","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"Kars M, Souverein PC, Herings RMC et al (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94:2729\u20132734. https:\/\/doi.org\/10.1210\/jc.2009-0177","journal-title":"J Clin Endocrinol Metab"},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","volume":"48","author":"W Huang","year":"2019","unstructured":"Huang W, Molitch ME (2019) Pituitary tumors in pregnancy. Endocrinol Metab Clin North Am 48:569\u2013581. https:\/\/doi.org\/10.1016\/j.ecl.2019.05.004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1384_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s0015-0282(16)47888-x","volume":"41","author":"V Ruiz-Velasco","year":"1984","unstructured":"Ruiz-Velasco V, Tolis G (1984) Pregnancy in hyperprolactinemic women. Fertil Steril 41:793\u2013805. https:\/\/doi.org\/10.1016\/s0015-0282(16)47888-x","journal-title":"Fertil Steril"},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/BF01727477","volume":"65","author":"P Krupp","year":"1987","unstructured":"Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65:823\u2013827. https:\/\/doi.org\/10.1007\/BF01727477","journal-title":"Klin Wochenschr"},{"key":"1384_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","volume":"23","author":"BG Sant\u2019 Anna","year":"2020","unstructured":"Sant\u2019 Anna BG, Musolino NRC, Gadelha MR et al (2020) A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 23:120\u2013128. https:\/\/doi.org\/10.1007\/s11102-019-01008-z","journal-title":"Pituitary"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1055\/s-0043-112861","volume":"125","author":"B Araujo","year":"2017","unstructured":"Araujo B, Belo S, Carvalho D (2017) Pregnancy and tumor outcomes in women with prolactinoma. Exp Clin Endocrinol Diabetes 125:642\u2013648. https:\/\/doi.org\/10.1055\/s-0043-112861","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/09513590.2016.1254177","volume":"33","author":"A Rastogi","year":"2017","unstructured":"Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33:270\u2013273. https:\/\/doi.org\/10.1080\/09513590.2016.1254177","journal-title":"Gynecol Endocrinol"},{"key":"1384_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","volume":"68","author":"A Colao","year":"2008","unstructured":"Colao A, Abs R, B\u00e1rcena DG et al (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68:66\u201371. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03000.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1384_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/ajo.13070","volume":"60","author":"SM O\u2019Sullivan","year":"2020","unstructured":"O\u2019Sullivan SM, Farrant MT, Ogilvie CM et al (2020) An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. Aust N Z J Obstet Gynaecol 60:405\u2013411. https:\/\/doi.org\/10.1111\/ajo.13070","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A, Di Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023\u20132033. https:\/\/doi.org\/10.1056\/NEJMoa022657","journal-title":"N Engl J Med"},{"key":"1384_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1210\/jc.2012-3039","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Perone Y, Di Sarno A et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372\u2013379. https:\/\/doi.org\/10.1210\/jc.2012-3039","journal-title":"J Clin Endocrinol Metab"},{"key":"1384_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","volume":"73","author":"M Lebbe","year":"2010","unstructured":"Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 73:236\u2013242. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03808.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1384_CR16","first-page":"166","volume":"24","author":"MS Cattaruzza","year":"2000","unstructured":"Cattaruzza MS, Spinelli A (2000) Spontaneous abortion in Italy: social differences and temporal trends. Epidemiol Prev 24:166\u2013171","journal-title":"Epidemiol Prev"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0890-6238(02)00055-2","volume":"16","author":"E Ricci","year":"2002","unstructured":"Ricci E, Parazzini F, Motta T et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16:791\u2013793. https:\/\/doi.org\/10.1016\/s0890-6238(02)00055-2","journal-title":"Reprod Toxicol"},{"key":"1384_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","volume":"10","author":"E Robert","year":"1996","unstructured":"Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333\u2013337. https:\/\/doi.org\/10.1016\/0890-6238(96)00063-9","journal-title":"Reprod Toxicol"},{"key":"1384_CR19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens P et al (2000) Maternal age and fetal loss: population based register linkage study. BMJ 320:1708\u20131712. https:\/\/doi.org\/10.1136\/bmj.320.7251.1708","journal-title":"BMJ"},{"key":"1384_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/dmcn.12133","volume":"55","author":"FB Diepeveen","year":"2013","unstructured":"Diepeveen FB, De Kroon MLA, Dusseldorp E, Snik AFM (2013) Among perinatal factors, only the apgar score is associated with specific language impairment. Dev Med Child Neurol 55:631\u2013635. https:\/\/doi.org\/10.1111\/dmcn.12133","journal-title":"Dev Med Child Neurol"},{"key":"1384_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00404-014-3210-z","volume":"290","author":"C Hurault-Delarue","year":"2014","unstructured":"Hurault-Delarue C, Montastruc J-L, Beau A-B et al (2014) Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 290:263\u2013270. https:\/\/doi.org\/10.1007\/s00404-014-3210-z","journal-title":"Arch Gynecol Obstet"},{"key":"1384_CR22","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger A, Broersen LHA, Biermasz NR et al (2021) ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol 185:G1\u2013G33. https:\/\/doi.org\/10.1530\/EJE-21-0462","journal-title":"Eur J Endocrinol"},{"key":"1384_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","volume":"72","author":"MSB Huda","year":"2010","unstructured":"Huda MSB, Athauda NB, Teh MM et al (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72:507\u2013511. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03657.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1384_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1530\/acta.0.1000337","volume":"100","author":"HK Rjosk","year":"1982","unstructured":"Rjosk HK, Fahlbusch R, von Werder K (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol (Copenh) 100:337\u2013346. https:\/\/doi.org\/10.1530\/acta.0.1000337","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1384_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","volume":"45","author":"WJ Jeffcoate","year":"1996","unstructured":"Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J (1996) Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45:299\u2013303. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.00824.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1384_CR26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12370","volume":"80","author":"M-E Domingue","year":"2014","unstructured":"Domingue M-E, Devuyst F, Alexopoulou O et al (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 80:642\u2013648. https:\/\/doi.org\/10.1111\/cen.12370","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01384-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:14:54Z","timestamp":1717488894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01384-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"9 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no actual or perceived conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol was in accordance with the principles of the Declaration of Helsinki and was approved by the local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}